Messenger Ribonucleic Acid (mRNA) Capping Enzyme Global Market Report 2025
상품코드:1855920
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
전령 리보핵산(mRNA) 캡핑 효소 시장 규모는 최근 급속도로 확대되고 있습니다. 2024년 8억 9,000만 달러에서 2025년에는 10억 2,000만 달러에 달하고, CAGR 14.6%로 확대될 전망입니다. 실적기간 내 성장은 분자생물학과 생명공학 연구의 확대, 유전공학과 합성생물학의 진보, 백신연구에의 응용 증가, RNA 연구에 대한 정부 및 민간자금 증가, 바이오의약품 제조의 성장에 의해 발생하였습니다.
전령 리보핵산(mRNA) 캡핑 효소 시장 규모는 앞으로 수년간 급성장할 것으로 예측됩니다. 2029년에는 연평균 복합 성장률(CAGR) 14.2%로 17억 3,000만 달러로 성장할 전망입니다. 예측기간 동안의 성장은 RNA 기반의 의약품 개발 투자 증가, mRNA 기반 임상시험의 파이프라인 확대, 맞춤 및 정밀의료의 성장, mRNA의 안정성과 번역 효율성에 대한 주목 증가, mRNA 백신 및 치료제의 광범위한 채용에 의해 지원될 것으로 예측됩니다. 예측 기간 동안 예상되는 주요 동향으로는 인공지능과 머신러닝과의 통합, 체외 전사(IVT) 기술 개발, 차세대 효소 캡핑 시스템, 합성 캡 아날로그 및 공동 전사 캡핑 기술 개발, 효소 설계 혁신 등이 있습니다.
맞춤 의료의 채택 증가는 앞으로 수년간 전령 리보핵산 캡핑 효소 시장의 성장을 지원할 것으로 예측됩니다. 맞춤 의료는 개인의 유전자 프로파일, 라이프 스타일 및 환경 요인에 따라 치료를 조정하는 의료 접근법입니다. 이 접근법은 환자 고유의 치료 요구를 보다 정확하게 파악하고 보다 효과적인 치료 결과를 제공하는 유전자 검사 기술의 발전으로 인기를 끌고 있습니다. 전령 리보핵산 캡핑 효소는 치료용 전령 리보핵산의 안정성과 기능성을 향상시키고 개별 치료 요건을 충족하도록 설계된 단백질로의 효율적인 번역을 보장함으로써 맞춤 의료에 기여합니다. 예를 들어, 2024년 2월 미국에 본사를 둔 비영리 단체인 맞춤의료연합(Personalized Medicine Coalition)은 식품의약국이 2023년에 희소질환 환자를 위해 16개의 신규 맞춤 치료를 승인했다고 보고했습니다. 따라서 맞춤 의료의 채용 확대는 전령 리보핵산 캡핑 효소 시장의 확대에 기여하고 있습니다.
전령 리보핵산 캡핑 효소 시장의 주요 기업은 광온도 캡핑 기술과 같은 첨단 솔루션을 도입하여 온도 관리 물류에 대한 의존성을 줄이고 생산과 보관을 간소화합니다. 이러한 광온도 솔루션은 다양한 온도 범위에서 효소의 안정성과 성능을 유지하도록 설계되었으며 다양한 생산 및 보관 조건에 적합합니다. 예를 들어, 미국에 본사를 둔 생명과학 기업인 New England Biolabs는 2022년 8월 기존 전령 리보핵산의 캡핑 방법의 한계를 해결하는 새로운 효소 도구인 Faustovirus Capping Enzyme을 발표했습니다. 이 효소는 RNA 트리포스파타제, 구아닐릴트랜스퍼라제, N7-구아닌메틸트랜스퍼라제 활성을 가진 단일 서브유닛을 포함하며, 20-55°C의 온도 범위에서 효과적으로 기능합니다. 이것은 Cap-0 구조의 합성을 가능하게 하며, 단일 포트 반응에 의해 Cap-1 구조를 생성하기 위해 추가 효소와 병용될 수 있습니다. 이 기술 혁신은 현재 생산 공정에 원활하게 통합되어 캡핑 효율을 향상시키고 효소 소비를 최대 50% 줄이며 위험한 용매를 필요로 하지 않습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 전령 리보핵산(mRNA) 캡핑 효소 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 : 성장률 분석
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 실적 : 규모와 성장(2019-2024년)
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 전령 리보핵산(mRNA) 캡핑 효소 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
재조합 전령 리보핵산(mRNA) 캡핑 효소
천연 전령 리보핵산(mRNA) 캡핑 효소
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
연구개발
치료
진단
기타 용도
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제약 및 생명공학 기업
연구기관
제조 수탁 기관(CMOS)
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 세분화 : 재조합 전령 리보핵산(mRNA) 캡핑 효소 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
백시니아 캡핑 효소(VCE)
RNA 트리포스파타제
구아닐릴트랜스퍼라제
(구아닌-N7)-메틸트랜스퍼라제
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 세분화 : 천연 전령 리보핵산(mRNA) 캡핑 효소 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
캡0 캡핑효소
캡1 캡핑 효소
캡2 캡핑 효소
제7장 지역별/국가별 분석
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 전령 리보핵산(mRNA) 캡핑 효소 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
전령 리보핵산(mRNA) 캡핑 효소 시장 : 경쟁 구도
전령 리보핵산(mRNA) 캡핑 효소 시장 : 기업 프로파일
Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석
Takara Bio Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Aldevron : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
New England Biolabs Inc.
CellScript Inc.
Krishgen Biosystems
Yeasen Biotechnology Co. Ltd.
Novoprotein Scientific Inc.
TriLink Biotechnologies LLC
Jena Bioscience GmbH
OZ Biosciences
SBS Biotech Ltd.
Vazyme Biotech Co. Ltd.
Enzynomics Inc.
Creative Enzymes
Canvax Biotech SL
APExBIO Technology LLC
BOC Sciences
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
전령 리보핵산(mRNA) 캡핑 효소 시장(2029년) : 새로운 기회를 제공하는 국가
전령 리보핵산(mRNA) 캡핑 효소 시장(2029년) : 새로운 기회를 제공하는 부문
전령 리보핵산(mRNA) 캡핑 효소 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Messenger ribonucleic acid (mRNA) capping enzyme is a crucial enzyme that modifies newly synthesized mRNA molecules in eukaryotic cells. It adds a chemical structure called the 5' cap to the beginning of the mRNA strand shortly after transcription from DNA. This capping process involves attaching a modified guanine nucleotide to the mRNA through a unique 5'-5' linkage.
The primary product types of mRNA capping enzymes are recombinant and natural enzymes. Recombinant mRNA capping enzymes are genetically engineered proteins that specifically catalyze the capping of RNA molecules. These enzymes are used in research and development, therapeutics, diagnostics, and other applications. Key end-users include pharmaceutical and biotechnology companies, research institutions, and contract manufacturing organizations (CMOs).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The messenger ribonucleic acid (mRNA) capping enzyme market research report is one of a series of new reports from The Business Research Company that provides messenger ribonucleic acid (mRNA) capping enzyme market statistics, including messenger ribonucleic acid (mRNA) capping enzyme industry global market size, regional shares, competitors with a messenger ribonucleic acid (mRNA) capping enzyme market share, detailed messenger ribonucleic acid (mRNA) capping enzyme market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mRNA) capping enzyme industry. This messenger ribonucleic acid (mRNA) capping enzyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The messenger ribonucleic acid (mRNA) capping enzyme market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. Growth in the historic period was driven by the expansion of molecular biology and biotechnology research, advances in genetic engineering and synthetic biology, increasing applications in vaccine research, rising government and private funding for RNA research, and growth in biopharmaceutical manufacturing.
The messenger ribonucleic acid (mRNA) capping enzyme market size is expected to see rapid growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. Growth in the forecast period is expected to be supported by rising investment in RNA-based drug development, an expanding pipeline of mRNA-based clinical trials, growth in personalized and precision medicine, increasing focus on mRNA stability and translational efficiency, and wider adoption of mRNA vaccines and therapeutics. Key trends anticipated for the forecast period include integration with artificial intelligence and machine learning, development of in-vitro transcription (IVT) technologies, next-generation enzymatic capping systems, advancements in synthetic cap analogs and co-transcriptional capping technologies, and innovation in enzyme design.
The increasing adoption of personalized medicine is expected to support the growth of the messenger ribonucleic acid capping enzyme market in the coming years. Personalized medicine is a medical approach that tailors treatment based on an individual's genetic profile, lifestyle, and environmental factors. This approach is gaining popularity due to progress in genetic testing technologies, which allow for more precise identification of patient-specific treatment needs, leading to more effective therapeutic outcomes. Messenger ribonucleic acid capping enzymes contribute to personalized medicine by enhancing the stability and functionality of therapeutic messenger ribonucleic acid, ensuring efficient translation into proteins designed to meet individual treatment requirements. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the United States, reported that the Food and Drug Administration approved sixteen new personalized treatments for rare disease patients in 2023, a notable increase from six approvals in 2022. Therefore, the growing adoption of personalized medicine is contributing to the expansion of the messenger ribonucleic acid capping enzyme market.
Leading companies in the messenger ribonucleic acid capping enzyme market are introducing advanced solutions, such as broad temperature capping technologies, to simplify production and storage by reducing reliance on controlled temperature logistics. These broad temperature solutions are designed to maintain enzyme stability and performance across a wide range of temperatures, making them suitable for diverse production and storage conditions. For instance, in August 2022, New England Biolabs, a life sciences company based in the United States, introduced the Faustovirus Capping Enzyme, a novel enzymatic tool that addresses limitations in traditional messenger ribonucleic acid capping methods. This enzyme contains a single subunit with RNA triphosphatase, guanylyltransferase, and N7-guanine methyltransferase activities, and functions effectively within a temperature range of twenty to fifty-five degrees Celsius. It enables the synthesis of Cap-0 structures and can be used with an additional enzyme to generate Cap-1 structures through a single-pot reaction. This innovation integrates seamlessly into current production processes, offering improved capping efficiency, reducing enzyme consumption by up to fifty percent, and eliminating the need for hazardous solvents.
In February 2025, TriLink BioTechnologies, a biotechnology company based in the United States, formed a partnership with Aldevron to incorporate CleanCap messenger ribonucleic acid capping technology into Aldevron's development and manufacturing services. The collaboration aims to improve messenger ribonucleic acid yield, streamline processing, and deliver higher-quality therapeutics using TriLink's CleanCap analogs, which include CleanCap M6, AG three prime OMe, AG, and AU. These analogs provide over ninety-five percent capping efficiency and enhance expression levels. Aldevron is a contract development and manufacturing organization based in the United States.
Major players in the messenger ribonucleic acid (mRNA) capping enzyme market are Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Takara Bio Inc., Aldevron, New England Biolabs Inc., CellScript Inc., Krishgen Biosystems, Yeasen Biotechnology Co. Ltd., Novoprotein Scientific Inc., TriLink Biotechnologies LLC, Jena Bioscience GmbH, OZ Biosciences, SBS Biotech Ltd., Vazyme Biotech Co. Ltd., Enzynomics Inc., Creative Enzymes, Canvax Biotech SL, APExBIO Technology LLC, BOC Sciences, KACTUS Biosystems.
North America was the largest region in the messenger ribonucleic acid (mRNA) capping enzyme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in messenger ribonucleic acid (mRNA) capping enzyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the messenger ribonucleic acid (mRNA) capping enzyme market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The messenger ribonucleic acid (mRNA) capping enzyme market consists of sales of inorganic pyrophosphatase, murine RNase inhibitor, and polymerase chain reaction enzymes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Messenger Ribonucleic Acid (mRNA) Capping Enzyme Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on messenger ribonucleic acid (mrna) capping enzyme market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for messenger ribonucleic acid (mrna) capping enzyme ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The messenger ribonucleic acid (mrna) capping enzyme market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
4. Messenger Ribonucleic Acid (mRNA) Capping Enzyme Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Messenger Ribonucleic Acid (mRNA) Capping Enzyme Growth Analysis And Strategic Analysis Framework
5.1. Global Messenger Ribonucleic Acid (mRNA) Capping Enzyme PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
